| HOME >> BIOLOGY >> TECHNOLOGY |
In the U.S. study, rates of discontinuation due to AEs for the placebo, desvenlafaxine 50 mg/day and desvenlafaxine 100 mg/day groups were 3 percent, 3 percent and 7 percent, respectively. In the international study, these rates for the placebo, desvenlafaxine 50 mg/day and desvenlafaxine 100 mg/day groups were 3 percent, 5 percent and 7 percent, respectively.
Adverse events in both of these studies that were reported by at least five percent of the subjects and twice the rate of placebo included asthenia, anorexia, anxiety, dizziness and insomnia. Events also reported by at least five percent of the subjects and twice the rate of placebo in the international study were nausea, somnolence and abnormal ejaculation; and in the U.S. study they were constipation, dry mouth, myalgia, impotence and sweating. In the U.S. study, nausea was not among the adverse events reported by at least five percent of the subjects and twice the rate of placebo.
A PDF version of the poster presentation of this data will be available on Wyeth's website, http://www.Wyeth.com, shortly after it is presented today, beginning at 5:30 p.m., Eastern U.S. Time.
"Major depressive disorder is a chronic and disabling disease that can cause significant distress and impair an individual's daily functioning," says Michael Liebowitz, M.D., lead author of the poster and a professor of clinical psychiatry. "Unfortunately, research and clinical practice suggest that a large percentage of patients with major depression do not respond to initial antidepressant therapy, leaving these patients still struggling with symptoms of depression. Clearly, there is a need for additional treatment options."
Desvenlafaxine was discovered and developed by Wyeth Research. As a leader in neuroscience, the Company is committed to discovering and developing a broad range of treatments for mental illness.
About Antidepressants
A
'/>"/>
| SOURCE Wyeth Pharmaceuticals Copyright©2007 PR Newswire. All rights reserved |